期刊
TRENDS IN IMMUNOLOGY
卷 37, 期 6, 页码 349-351出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2016.04.008
关键词
-
类别
The overall mutational burden of a tumor is considered to be a predictive marker for the success of checkpoint blockade therapy. A recent study by McGranahan et al. reframes this notion by showing that clonal expression of neoantigens by tumor cells, rather than overall mutational burden, determines the response to checkpoint blockade therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据